HER2 negative breast cancer Diagnostics

Tissue Sample Collection

To determine whether breast cancer is HER2-negative, doctors need to examine a small piece of your tumor tissue. They obtain this sample either during a biopsy (a procedure where a needle or small surgical tool removes tissue) or during surgery if you've already had a tumor removed.2 A biopsy is often the first step after an abnormal mammogram or physical exam finding, while surgical samples come from procedures like lumpectomy or mastectomy.

The tissue sample is sent to a laboratory where specialists analyze it to look at the cancer cells under a microscope and perform additional tests to identify specific proteins and receptors on the cell surface. This detailed examination tells doctors exactly what kind of breast cancer you have.

HER2 Status Testing

Once the tissue sample reaches the laboratory, specialists run tests to check for the presence of HER2 protein. HER2 stands for human epidermal growth factor receptor 2, which is a protein that helps control how breast cells grow and repair themselves. In healthy cells, HER2 works normally, but when cancer cells make too much of it, the cancer becomes more likely to multiply and spread.2

If your test shows that your cancer cells aren't making a lot of extra HER2, your doctor will tell you that your breast cancer is HER2-negative. This classification is crucial because it tells your healthcare team which treatments will or won't work for you. Treatments that target HER2 proteins won't be effective if your cancer is HER2-negative, so your doctor will suggest different treatment options.2

Hormone Receptor Testing

Along with checking HER2 status, doctors also test for other important proteins called hormone receptors. These receptors respond to hormones in your blood, specifically estrogen and progesterone. Sometimes doctors refer to these separately as estrogen receptors (ER) and progesterone receptors (PR), but they often discuss all the different receptors together when describing your cancer.2

Your HER2-negative cancer will be classified as either hormone receptor-positive (HR-positive/HER2-negative) or hormone receptor-negative (HR-negative/HER2-negative). If your cancer is negative for HER2 and both types of hormone receptors, it's called triple-negative breast cancer.2 About 70% of breast cancers are HR-positive/HER2-negative, while only about 10 to 15% are HR-negative/HER2-negative or triple-negative.2

Understanding your complete receptor status—both HER2 and hormone receptors together—gives you and your doctors vital information about the biology of your cancer. This knowledge helps doctors decide which treatment is best to try first and what backup options you have if you need to try something different later.2

Additional Genetic Testing

In some cases, your doctor may look at other factors beyond HER2 and hormone receptors, including genetic changes in your cancer cells or other characteristics that could affect how quickly the cancer is likely to grow or spread.2 While there isn't a specific mutation that causes HER2-negative breast cancers in particular, inheriting gene mutations like BRCA1 or BRCA2 increases your overall risk of developing breast cancer.1

Imaging and Staging Tests

Beyond testing the cancer cells themselves, doctors use various imaging techniques to understand the size and location of your tumor and whether the cancer has spread. These tests help determine the stage of your cancer—information that's just as important as knowing your HER2 status. Common imaging tests include mammography, ultrasound, MRI scans, CT scans, and bone scans, depending on your individual situation and what doctors need to learn about your cancer.

The combination of tissue analysis (showing HER2 status and hormone receptors) and imaging (showing stage and spread) gives your medical team a complete picture of your cancer. This comprehensive understanding allows them to create a treatment plan tailored specifically to your situation.

Confirmed HER2-Negative Status

The most fundamental requirement for entering a HER2-negative breast cancer clinical trial is documented proof that your cancer is indeed HER2-negative. This means you must have had tissue testing that clearly shows your cancer cells don't contain high levels of the HER2 protein. Clinical trials typically require this testing to be recent and performed using standardized laboratory methods to ensure accuracy and consistency across all study participants.

Hormone Receptor Status Documentation

Many clinical trials for HER2-negative breast cancer are designed specifically for either hormone receptor-positive or hormone receptor-negative (triple-negative) subtypes. Therefore, you'll need clear documentation of whether your cancer cells have estrogen and progesterone receptors. This information determines which clinical trials you're eligible for, as treatments being studied often target specific receptor combinations.

Disease Stage and Spread Assessment

Clinical trials usually enroll patients at specific stages of cancer. Some trials focus on early-stage disease that hasn't spread beyond the breast, while others study advanced or metastatic breast cancer (cancer that has spread to other parts of the body). You'll need imaging tests and sometimes additional biopsies to document exactly where your cancer is located and whether it has spread to lymph nodes or other organs. These assessments help researchers ensure they're studying treatments in the right patient population.

Previous Treatment History

Many clinical trials have requirements about what treatments you've received in the past. Some trials are only open to patients who haven't had any treatment yet, while others specifically enroll people whose cancer has returned after previous therapy. Your medical records documenting all previous treatments—including surgery, chemotherapy, radiation, and hormone therapy—will be reviewed to confirm your eligibility.

Genetic Testing for Certain Trials

Some clinical trials target very specific genetic characteristics of cancer cells. For these studies, you might need additional genetic testing beyond the standard HER2 and hormone receptor tests. For example, trials studying PARP inhibitors often require testing to see if you have mutations in the BRCA1 or BRCA2 genes. Other trials might look for different genetic markers that could predict whether a particular experimental treatment will work.

Overall Health Assessment

Before enrolling in a clinical trial, you'll undergo tests to assess your overall health and how well your organs are functioning. These typically include blood tests to check your liver and kidney function, heart tests to ensure your heart is strong enough for certain treatments, and performance status evaluations to measure how well you can carry out daily activities. These assessments protect your safety by ensuring that you're healthy enough to receive the experimental treatment being studied.

The diagnostic requirements for clinical trials are more extensive than standard care because researchers need detailed, standardized information to understand how new treatments work. While this means more testing, participating in clinical trials gives you access to potentially beneficial new treatments that aren't yet widely available.

Prognosis

The outlook for HER2-negative breast cancer generally depends on several factors working together, rather than HER2 status alone. Breast cancer that's HER2-negative tends to have a better outlook than HER2-positive breast cancer because HER2-negative cancer is typically less aggressive.2 However, your individual prognosis depends on many other elements including the stage of cancer when it's discovered, whether the cancer is hormone receptor-positive or triple-negative, your overall health, how well the cancer responds to treatment, and whether it spreads to other parts of your body.

Hormone receptor-positive/HER2-negative breast cancer, which accounts for about 70% of all breast cancers, often has a favorable prognosis because there are many effective hormone-based treatments available.1 Triple-negative breast cancer (HR-negative/HER2-negative), which makes up about 11% of cases, can be more challenging to treat because it doesn't respond to hormone therapies or HER2-targeted treatments. However, treatment advances continue to improve outcomes for this subtype as well.1

Survival Rate

Most breast cancer diagnoses are HER2-negative, with about 4 out of 5 breast cancers falling into this category.2 When diagnosed early, HR-positive/HER2-negative breast cancer has a positive prognosis, meaning many people can expect favorable outcomes with appropriate treatment.3 Specific survival statistics vary widely based on the stage at diagnosis, whether the cancer has hormone receptors, and individual patient factors.

It's important to remember that survival statistics are based on large groups of people and may not reflect your personal situation. Your healthcare team can provide more personalized information about your outlook based on your specific cancer characteristics, overall health, and how you respond to treatment. Additionally, cancer treatments continue to improve, which means that survival rates are generally getting better over time as new therapies become available.